ReviewWorld journal of transplantation2013
Novel immunosuppressive agents in kidney transplantation.
Review in World journal of transplantation, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 3 syntheses or guidelines pooled it, 56 citations in OpenAlex.
- Polyclonal and monoclonal antibodies for treating acute rejection episodes in kidney transplant recipients.The Cochrane database of systematic reviews · 2017Pooled it
- Mycophenolic acid versus azathioprine as primary immunosuppression for kidney transplant recipients.The Cochrane database of systematic reviews · 2015Pooled it
- mTOR inhibitor versus mycophenolic acid as the primary immunosuppression regime combined with calcineurin inhibitor for kidney transplant recipients: a meta-analysis.BMC nephrology · 2015Pooled it
- Macrophage Actin Cytoskeleton in Chronic Rejection.Results and problems in cell differentiation · 2026Review
- Protein kinase C targeting of luminal (T-47D), luminal/HER2-positive (BT474), and triple negative (HCC1806) breast cancer cells in-vitro with AEB071 (Sotrastaurin) is efficient but mediated by subtype specific molecular effects.Archives of gynecology and obstetrics · 2022Article
- Risk Factors of Rejection in Renal Transplant Recipients: A Narrative Review.Journal of clinical medicine · 2022Review
- Utilization of Mycophenolic Acid, Azathioprine, Tacrolimus, Cyclosporin, Sirolimus, and Everolimus: Multinational Study.Frontiers in public health · 2021Article
- B cell phenotypes in baboons with pig artery patch grafts receiving conventional immunosuppressive therapy.Transplant immunology · 2018Article
- AAV9-mediated engineering of autotransplanted kidney of non-human primates.Gene therapy · 2017Article
- An enantioselective synthesis of the C3-C21 segment of the macrolide immunosuppressive agent FR252921.Tetrahedron letters · 2016Article
- Off-label use of the expensive orphan drug eculizumab in France 2009-2013 and the impact of literature: focus on the transplantation field.European journal of clinical pharmacology · 2016Article
- Successful living donor intestinal transplantation in cross-match positive recipients: Initial experience.World journal of gastrointestinal surgery · 2016Article
- Can We Repurpose FDA-Approved Alefacept to Diminish the HIV Reservoir?Immunotherapy (Los Angeles, Calif.) · 2015Article
- Risk factors for lung diseases after renal transplantation.Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2015Article
- An Anti-C1s Monoclonal, TNT003, Inhibits Complement Activation Induced by Antibodies Against HLA.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2015Article
- Biologics in renal transplantation.Pediatric nephrology (Berlin, Germany) · 2015Review
- Complement involvement in kidney diseases: From physiopathology to therapeutical targeting.World journal of nephrology · 2015Review
- Docetaxel Facilitates Endothelial Dysfunction through Oxidative Stress via Modulation of Protein Kinase C Beta: The Protective Effects of Sotrastaurin.Toxicological sciences : an official journal of the Society of Toxicology · 2015Article
- Tacrolimus prolonged release (Envarsus®): a review of its use in kidney and liver transplant recipients.Drugs · 2015Review
- Blockade of co-stimulation in chronic inflammatory diseases.Wiener medizinische Wochenschrift (1946) · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Excellent outcomes have been achieved in the field of renal transplantation. A significant reduction in acute rejection has been attained at many renal transplant centers using contemporary immunosuppressive, consisting of an induction agent, a calcineurin inhibitor, an antiproliferative agent plus or minus a corticosteroid. Despite improvements with these regimens, chronic allograft injury and adverse events still persist. The perfect immunosuppressive regimen would limit or eliminate calcineurin inhibitors and/or corticosteroid toxicity while providing enhanced allograft outcomes. Potential improvements to the calcineurin inhibitor class include a prolonged release tacrolimus formulation and voclosporin, a cyclosporine analog. Belatacept has shown promise as an agent to replace calcineurin inhibitors. A novel, fully-human anti-CD40 monoclonal antibody, ASKP1240, is currently enrolling patients in phase 2 trials with calcineurin minimization and avoidance regimens. Another future goal of transplant immunosuppression is effective and safe treatment of allograft rejection. Novel treatments for antibody mediated rejection include bortezomib and eculizumab. Several investigational agents are no longer being pursed in transplantation including the induction agents, efalizumab and alefacept, and maintenance agents, sotrastaurin and tofacitinib. The purpose of this review is to consolidate the published evidence of the effectiveness and safety of investigational immunosuppressive agents in renal transplant recipients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.